Latest news with #SairamAtluri
New Indian Express
6 days ago
- Health
- New Indian Express
Hyderabad startup reverses chronic liver failure in animal trials
HYDERABAD: A Hyderabad-based startup, Tulsi Therapeutics, has demonstrated the complete reversal of chronic liver failure in animal trials using an innovative stem cell-exosome therapy. Conducted on rats, the preclinical study showed 100% liver fibrosis reversal and zero mortality among treated subjects, in stark contrast to the untreated group that saw only 14% reversal and 43% deaths. Tulsi-28X is a first-in-class regenerative biologic derived from Wharton's Jelly mesenchymal stem cells and their native exosomes, a combination never before tested in any animal model globally. Tulsi Therapeutics, incubated at ASPIRE-BioNEST, University of Hyderabad, developed the platform entirely in India over three years. Chronic liver failure accounts for nearly 20% of all liver-related deaths globally, with liver transplantation being the only treatment. Founder and CEO of Tulsi Therapeutics Dr Sairam Atluri said, 'There have been individual successes with stem cells and exosomes, but we combined them because they operate through different mechanisms. This combination maximised the biological outcome and marks a major milestone for India's biotech sector.' Looking ahead, the chief scientific officer said the next goal is to initiate human clinical trials in partnership with Nizam's Institute of Medical Sciences (NIMS), with groundwork expected to take up to two years. The results were presented at the AASLD 2024 Liver Conference in San Diego and have also been accepted for publication in the Journal of Regenerative Medicine.
Time of India
7 days ago
- Health
- Time of India
City startup incubated at UoH develops stem cell treatment for chronic liver failure
Hyderabad: A startup incubated at the University of Hyderabad (UoH) successfully tested a new treatment for chronic liver failure using stem cells. Called Tulsi-28X, the treatment is touted to be the first in the world by the firm to use a special combination of stem cells and natural healing particles called exosomes. These are taken from a part of the umbilical cord known as Wharton's Jelly. Although the concept was born in the US, the entire platform was developed in India by Tulsi Therapeutics after three years of rigorous research at ASPIRE-BioNEST, UoH's biotech incubator. "We have done trials on rats. All animals treated with Tulsi-28X showed reversal of liver fibrosis, indicating liver regeneration, resulting in zero deaths, compared to only 14% reversal and 43% deaths in the untreated control group," Dr Sairam Atluri, founder & CEO of Tulsi Therapeutics, told TOI. The preclinical trial was conducted in collaboration with Indiana University, US, and PGIMER, Chandigarh. He said that this treatment method can be a game-changer as it would give a new lease of life to those with liver failure and waiting for transplantation. "Right now, the only treatment for liver failure is transplant. However, there are not enough donors, the treatment is very expensive, and it comes with various complications. The medicine that we developed can be administered intravenously," added Atluri, and said he moved from the US to India to work on this idea and bring it to life. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad The startup has applied to the Central Drugs Standard Control Organisation (CDSCO) for conducting human trials. "We are committed to developing world-class yet affordable regenerative solutions," said Dr Ravi Bonthala, chief scientific officer of the startup. "Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences."
